Cytokrom P450 (CYP) Hepatic Drug Metabolism. Medicines in plasma. Plasma concentration of a medicine. Eva Brittebo Dept Pharmaceutical Biosciences

Similar documents
Chapter 4. Drug Biotransformation

B. Incorrect! Compounds are made more polar, to increase their excretion.

accesalabs.c

Toxicant Disposition and Metabolism. Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine

Title of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009)

BIOMARKERS AND TOXICITY MECHANISMS 07 Mechanisms Metabolism & Detoxification. Luděk Bláha, PřF MU, RECETOX

METABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84

To understand the formulary process from the hospital perspective

Metabolic Changes of Drugs and Related Organic Compounds

DRUG METABOLISM AND PHARMACOKINETICS (DMPK) Lena Gustavsson, H. Lundbeck A/S, November 2015

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

Cytochrome P450 Drug Interaction Table Flockhart Table

Drug Interactions Year 2 Clinical Pharmacology

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. Tivozanib. PROTOCOL REF: MPHATIVOUR (Version No: 1.

Application of Pharmacogenetics Supplementary Worksheet

DOMCET Tablet / Suspension (Domperidone maleate + Paracetamol)

The importance of pharmacogenetics in the treatment of epilepsy

Mechanism of Detoxification

Core Safety Profile. Pharmaceutical form(s)/strength: Oral solution 10 mg /ml. Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml. Date of FAR:

CORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082

Drug Interactions Year 2 Clinical Pharmacology

Cytochrome P 450 Unique family of heme proteins present in bacteria, fungi, insects, plants, fish, mammals and primates. Universal oxygenases (oxygen-

EFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation

(piperaquine tetraphosphate/ dihydroartemisinin) Guide for Healthcare Professionals REVISED EDITION 2016

MEDCHEM 570. First Midterm. January 30, 2015

Drug Interactions and ORT

Genetics and Genomics: Influence on Individualization of Medication Regimes

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

Summary of Product Characteristics

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

Paracetamol Poisoning in Children

PHYSIOLOGY AND MAINTENANCE Vol. II Biotransformation of Xenobiotics and Hormones - Osmo Hanninen BIOTRANSFORMATION OF XENOBIOTICS AND HORMONES

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Data Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.

Chapter 9. Biotransformation

INTEGRATIVE MEDICINE URINE, SPOT Result Range Units

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each capsule contains PARACETAMOL 500mg For a full list of excipients, see section 6.1.

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Falk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick

Daclatasvir. Patient information. How to contact us

Objectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

Polar bodies are either introduced or unmasked, which results in more polar metabolites Phase I reactions can lead either to activation or

Psychotropic Drug Interactions Over the past 2 decades:

Quetiapine Case 1 Warfarin Jose de Leon, MD

Introduction to Detoxification Enzymes. Evolutionary Response to Chemicals in the Environment

UCLA Nutrition Bytes. Title. Permalink. Journal ISSN. Author. Publication Date. Grapefruit Juice and Some Oral Drugs: A Bitter Combination

Valproate Case 1: Pharmacokinetics Jose de Leon, MD

HUMAN BIOTRANSFORMATION. ANDREW PARKINSON, BRIAN W. OGILVIE, BRANDY L. PARIS, TIFFINI N. HENSLEY, and GREG J. LOEWEN XenoTech LLC, Lenexa, KS

5th European Summer School. Drug interactions. therapeutic Information

Summary of Product Characteristics

Early Life Development of Toxicokinetic Pathways: Framework Case Examples and Implications for Safety Assessment

NEW ZEALAND DATA SHEET

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

MODUS TABLETS. Medroxyprogesterone Tablets IP

JOHN HARGRAVE. Date of Birth : 31-Oct-1973 Sex : M Collected : 24-Aug BENTONS ROAD MOUNT MARTHA VIC Lab id: UR#:

Shared Care Guideline for Ranolazine in the Management of Stable Angina Pectoris

Nevirapine 200mg Tablet WHOPAR part 4 May 2005 Section 7 updated: May 2016 SUMMARY OF PRODUCT CHARACTERISTICS

PrimaCare Cold & Flu Relief Lemon Powder for Oral Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Panobinostat, Bortezomib and Dexamethasone

6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES

PHASE I Detoxification: The First Line of Defense

Octanol / Water Partitioning Coefficient logp and ClogP

Regulation of P450. b. competitive-inhibitor but not substrate. c. non-competitive inhibition. 2. Covalent binding to heme or protein

Understanding the Benefits and Risks

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Drug Interactions Keeping it all Straight. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

Vandetanib in Thyroid carcinoma

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention

SUMMARY OF PRODUCT CHARACTERISTICS

NEW ZEALAND DATA SHEET

Elements for a Public Summary. Overview of disease epidemiology

Ingrezza. (valbenazine) New Product Slideshow

MODULE No.26: Drug Metabolism

EFFECTIVE SHARED CARE AGREEMENT. July Dronedarone (Multaq ) For the treatment and management of atrial fibrillation

QT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency

New Zealand Datasheet

Active ingredients: Pantoprazole sodium 45.1 mg equivalent to 40 mg Pantoprazole base

Drug Metabolism Phase 2 conjugation reactions. Medicinal chemistry 3 rd stage

INTRODUCTION TO PHARMACOKINETICS

Granisetron Kabi, 1mg/ml, concentrate for solution for injection/infusion

Selected Properties of Daclatasvir

Who remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?

Excipient with known effect: One tablet contains mg lactose monohydrate.

1. MEDICINAL PRODUCT FOR COMPASSIONATE USE

Pharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )

Mechanisms of Arrhythmogenesis: Focus on Long QT Syndrome (LQTS)

ZOFRAN TABLETS GlaxoSmithKline

Drug Interactions: Let me count the ways

Cytochrome P450 Suppression in Human Hepatocyte Cultures by Small and Large Molecules. George Zhang, Ph.D. April 18, 2012

Updated Guidelines for Managing HIV/HCV Co-Infection

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

TdP Mechanisms and CiPA

Transcription:

Hepatic Drug Metabolism Eva Brittebo Dept Pharmaceutical Biosciences Background Cytochrome P450 (CYP) Liver metabolism Liver toxicity Inhibition and induction Polymorphism 15-05-13 2 Plasma concentration of a medicine Medicines in plasma Absorption Distribution Metabolism Excretion Dosing interval = ADME 3 Phase I metabolism Introduction of a functional group OH - OH - NH 2 - SH - epoxid - COOH Phase II metabolism Conjugation of an endogenous water-soluble compound Drug metabolism enzymes Cytokrom P450 (CYP) CYP OH -glutathione -glucuronic acid -acetyl -sulfate Guengerich, Chem. Res. Toxicol. 2008, 21, 70 83

CYP (cytochrome 450) a superfamily of drug metabolism enzymes Major hepatic CYPs Metabolism of drugs, other xenobiotics and endogenous substrates CYP1 family (> 40 % identity) CYP1A subfamily (> 55% identity) CYP1A1 individual gene/protein CYP1A1*1 allele variant CYP 1A2 CYP 2C9 CYP 2C19 CYP 2D6 CYP 3A4 >90% of currently used drugs 15-05-13 7 15-05-13 8 CYP3A4 Interindividual differences in hepatic drug metabolism A major hepatic CYP metabolizes more than 120 drugs can be inhibited and induced 15-05-13 9 Polymorphism Exposure to CYP-inducing chemicals F. Peter Guengerich, The AAPS Journal 2006; 8 (1) The plant-animal warfare CYP developed in response to toxic substances in plants that had to be detoxified by animals From Boelsterli: Mechanistic Toxicology

CYP and drug-induced liver damage CYP bioactivation of paracetamol (Alvedon) Overdose! heptatotoxicity and acute liver failure 0-24 h nausea, abdominal pain 18-24 h less symptoms, ALAT/ASAT 72-96 h liver encephalopathy, jaundice, coagulation disturbance Risk factors: Alcohol, CYP-inducing drugs Antidote: N-acetylcysteine (NAC) Low dose paracetamol - detoxication Overdose paracetamol Saturated Overdose paracetamol - metabolic activation Overdose paracetamol - metabolic activation CYP2E1 CYP2E1 saturated Liver damage

Overdose paracetamol - metabolic activation Drug-related problems due to CYP CYP2E1 CYPs are Saturable -> dose-dependent kinetics Inhibitable -> drug-drug (food) interactions Inducible -> drug-drug (food) interactions Polymorphic -> interindividual metabolism antidot N-acetylcysteine Read FASS Liver damage A patient s medication Drug-drug interactions due to hepatic CYP inhibition hormone antifungal drug antibiotic Medroxyprogesterone Cefaclor Ketoconazole antihistamine Terfenadine 15-05-13 21 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day of treatment Monahan BP et al. JAMA From 1990;264:2788 2790 Centers for Education & Research on Therapeutics Medroxyprogesterone Medroxyprogesterone Not associated with arrhythmia Cefaclor Ketoconazole Cefaclor Ketoconazole Terfenadine First non-sedating antihistamine Terfenadine 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day of treatment Monahan BP et al. JAMA 1990;264:2788 2790 From Centers for Education & Research on Therapeutics 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Day of treatment Monahan BP et al. JAMA 1990;264:2788 2790 From Centers for Education & Research on Therapeutics

Ketoconazole + Terfenadine " ketoconazole inhibits liver CYP3A4 " decreased liver metabolism of terfendine " increased plasma concentrations of terfenadine " K + channel is blocked " prolonged QT intervals Drug withdrawals due to drug drug interactions Withdrawn Drug Use Drug-drug interaction via CYP inhibition 1998 Terfenadine Antihistamine Arrhythmias 1998 Mibefradil Calcium-channel blocker Arrhythmias 1999 Astemizole Antihistamine Arrhythmias 1999 Grepafloxacin Fluoroquinolone antibiotic Arrhythmias Monahan et al., JAMA 1990 Torsades de Pointes (twisting the points) 2000 Cisapride Gastroesophageal reflux disease Arrhythmias 80 deaths Food - drug interactions due to hepatic CYP inhibition Grape fruit drug interaction Dihydroxybergamottin in grape fruit CYP3A4 inhibitor 12-fold increase of some drug plasma concentrations 15-05-13 27 15-05-13 28 Hepatic CYP enzyme induction and drugs CYP gene regulation CYP genes can be upregulated by drugs and chemicals via ligand-receptor interaction CYP3 is induced by dexamethasone, phenobarbital, phenytoin, rifampicin, St John s wort etc CYP1 is induced by dioxin, PCB, DDT etc 15-05-13 29 15-05-13 30

Drug-drug interaction due to induction of CYP3A Induction of hepatic CYP3A4 and drug-drug interaction " increased metabolism of oral contraceptives decreased plasma level! pregnancy " increased metabolism of HIV-protease inhibitors decreased plasma level! resistance 15-05-13 31 CYP polymorphism and drugs CYP2D6 polymorphism Poor metabolizers (PM) Absent in 7% of Caucasians* Absent in 1 2% non-caucasians Ultrarapid metabolizers (URM) Hyperactive in up to 30% of North Africa, East Africa and Middle East 15-05-13 33 * In the United States, "Caucasian" is used primarily as a distinction loosely based on skin color alone for a group commonly refered to as Whites. In Britain, "Caucasian" follows the North American definition, but in continental Europe, "Caucasian" currently refers exclusively to people who are from the Caucasus Hepatic CYP2D6 and nortriptyline Preclinical drug development antidepressant drug 5-10 % of the Europeans lack CYP2D6 nortriptyline cannot be metabolized! 100% increased plasma concentration dose adaptation Approval or rejection of new drug candidates metabolized by polymorphic CYP forms? Consider the potential drug-drug interactions!